Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics Inc (DE:2LB)
FRANKFURT:2LB
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 263.50M | $ 164.07M | $ 1.19M | $ 0.00 | $ 0.00 |
| Gross Profit | $ 256.22M | $ 40.08M | $ -9.57M | $ 0.00 | $ 0.00 |
| Operating Income | $ -403.36M | $ -395.28M | $ -460.56M | $ -398.88M | $ -342.70M |
| EBITDA | $ -357.11M | $ -351.67M | $ -427.43M | $ -377.74M | $ -328.72M |
| Net Income | $ -390.98M | $ -372.18M | $ -444.04M | $ -395.89M | $ -342.25M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 296.98M | $ 323.78M | $ 279.87M | $ 471.85M | $ 504.41M |
| Total Assets | $ 913.17M | $ 910.43M | $ 780.35M | $ 663.98M | $ 777.33M |
| Total Debt | $ 48.44M | $ 58.26M | $ 75.86M | $ 85.45M | $ 71.53M |
| Net Debt | $ -114.63M | $ -57.43M | $ -39.03M | $ -146.28M | $ -6.70M |
| Total Liabilities | $ 214.59M | $ 200.02M | $ 195.74M | $ 164.34M | $ 155.67M |
| Stockholders' Equity | $ 698.58M | $ 710.40M | $ 584.61M | $ 499.64M | $ 621.66M |
| Cash Flow | |||||
| Free Cash Flow | $ -336.24M | $ -364.05M | $ -384.11M | $ -313.18M | $ -265.51M |
| Operating Cash Flow | $ -302.41M | $ -352.98M | $ -361.82M | $ -292.76M | $ -227.94M |
| Investing Cash Flow | $ 47.50M | $ -96.41M | $ -155.24M | $ 256.45M | $ 132.00K |
| Financing Cash Flow | $ 300.77M | $ 390.66M | $ 462.96M | $ 190.15M | $ 239.27M |